Colleagues Some good news: I had a meeting with the #UKHSA this week to present my root cause analysis on #AMR. I was met by insightful...

Colleagues I’ve been wading through the UK #governments second 5-year anti-AMR action plan, “Confronting #AntimicrobialResistance 2024-20...

The case for widening the #intravesical approach to #bladder diseases and disorders In the European Association of #Urology 2024 conference, intravesical chemotherapy “took centre stage:” https://www.linkedin.com/pulse/eau24-expert-commentary-professor-fufu-zheng-nmibc-postoperative-i6xre?trk=organization_guest_main-feed-card_feed-article-content The case for their use in uro-oncology was made over 60 years ago with the introduction of Mitiomycin C. The value in delivering d

On the day of the UK’s launch of its new #AMR 5-year plan, I offer this account as it is closely linked in attempting to reduce the incidences of CAUTI, and thus, incident AMR risks. Here’s some food for thought Patients and health services suffer the scourge of CAUTI in both hospitals and communities. No approved strategy has made a substantial difference. Various alternatives exist but need unblocking by officialdom. Here’s a selection: 1 - #Catheter cleaning: To prevent

I offer this “case report” and cautionary note to dedicated doctors with inventive minds. For many years in UK medicine, the most...

UroPharma produced #intravesical drug-delivery technology to bring, under licence, better cystitis (lower #UTI) treatments. For decades,...

#Epithelia line tissue surfaces that the outside world can directly access, such as skin, sclera, mouth, gut, vagina, #bladder and...

When we find a solution to a problem, naturally we look to the same approach for the next similar challenge. #Antibiotics changed the...

The distal urethra is a residency for #bacteria, mostly commensals, but sometimes potential uropathogens move in. #Catheterisation hygiene cleans the skin around the urethral meatus but does not remove bacteria residing in the distal urethra. Many people have focused time, effort and money on coatings that are supposed to prevent such bacteria surviving #catheter entry into the #bladder. Such a #coating would need to kill the potential pathogens before they are transferred fr

By Prof. Scott Glickman If a drug treatment for #cystitis is approved by a patient safety regulatory agency, without evidence that it can produce cure, who, if anyone, actually is, or should be responsible for an infection recurrence with it? I ask because I see no convincing evidence that any approved oral #antibiotic treatment has ever come with evidence that it reliably cures cystitis (i.e. produces pathogen annihilation). Of course, I see symptom recovery, but notwithst

Homeostatic mechanisms optimise our cellular chemistry. #antibiotics treatments are developed specifically to work in our narrow-band homeostatic chemical milieu to be delivered through blood to #infection sites for intimate combat with #bacterial invaders. With #cystitis, the bacteria are planktonic in urine and attached to urothelial cell membranes, so are too far away to be influenced by that approach. For #antibiotic tablets to have any chance to be effective against cy

I ask you to start the new year with a fresh look at cystitis and its management. While all the following are true: • The bladder is a soluble waste storage “bin.” • Urine is liquid metabolic waste dross. • Cystitis is a scourge. • Antibiotic stewardship must protect against over-use and • Symptom relief and clinical recovery are treatment goals. These facts haven’t helped us address cystitis recurrences, urosepsis or reduce AMR, so consider these facts, too: • Cystitis trea

From our Chief Medical Director, Professor Scott Glickman: With people working on AMR from cystitis treatments, I would be grateful to discuss the following conundrum. My analysis indicates that the oral/systemic route of administration is critically flawed by rate-limited initial drug filtration and ureteric drip-feed of antibiotic into urinary pools of sufficient volumes to delay it reaching MIC, and with its fluctuant pH likely dynamically altering MIC in-vivo as well, thu

From our CMO Professor Scott Glickman Colleagues: In medical and surgical services spanning primary through intensive care, we are dogged by UTI with their acute and long-term complications: treatment failures, recurrences, urosepsis, antimicrobial resistance (AMR) and high costs. Despite continuous improvements in antibiotic stewardship, these problems show little sign of abating. Something else must be involved. Antibiotic overuse and misuse shouldn’t be blamed exclusively